Intellia Therapeutics NTLA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$394.6M+25.0% | -$412.69M+20.5% | -$445.81M+14.6% | -$480.19M+5.6% | -$525.91M-8.3% | ||
| $9.48M-7.6% | $9.78M-4.9% | $9.96M-2.1% | $10.16M+3.0% | $10.26M+8.8% | ||
| $71.86M-49.4% | $80.22M-48.0% | $103.1M-31.1% | $123.11M-15.3% | $141.94M+0.7% | ||
| -$363.15M+3.7% | -$394.74M-13.1% | -$410.65M-15.1% | -$418.58M-12.1% | -$377.15M+7.0% | ||
| $473K-88.2% | $1.13M-80.5% | $1.98M-68.6% | $3.23M-65.5% | $4.01M-68.3% | ||
| $200.75M-6.2% | $228.77M+82.2% | $352.8M— | $345.09M— | $213.99M— | ||
| $165.06M+31.3% | $131.49M-29.2% | $131.83M-54.5% | $99.16M-56.3% | $125.76M-33.1% | ||
| —— | —— | —— | —— | —— | ||
| -$363.63M+4.6% | -$395.87M-11.6% | -$412.63M-13.7% | -$421.82M-10.2% | -$381.16M+8.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Intellia Therapeutics's cash flow data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.